Cogent Biosciences Inc
For the period ended Dec 31, 2023. Filed Feb 26, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 26, 2024
COGT$31.64-5.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except share and per share amounts)
| Year Ended December 31, | |||
|---|---|---|---|
| 2023 | 2022 | 2021 | |
| Operating expenses: | |||
| Research and development | $173,755 | $121,627 | $55,913 |
| General and administrative | 34,375 | 26,212 | 19,638 |
| Total operating expenses | 208,130 | 147,839 | 75,551 |
| Loss from operations | (208,130) | (147,839) | (75,551) |
| Other income: | |||
| Interest income | 13,077 | 3,989 | 467 |
| Other income, net | 943 | 2,249 | 2,468 |
| Change in fair value of CVR liability | 1,700 | 1,360 | 343 |
| Total other income, net | 15,720 | 7,598 | 3,278 |
| Net loss | $(192,410) | $(140,241) | $(72,273) |
| Net loss per share attributable to common stockholders, basic and diluted | $(2.42) | $(2.39) | $(1.87) |
| Weighted average common shares outstanding, basic and diluted | 79,657,942 | 58,739,713 | 38,730,813 |
| Comprehensive loss: | |||
| Net loss | $(192,410) | $(140,241) | $(72,273) |
| Other comprehensive loss | |||
| Net unrealized gains (losses) on marketable securities | 350 | (104) | — |
| Total other comprehensive loss | 350 | (104) | — |
| Comprehensive loss | $(192,060) | $(140,345) | $(72,273) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.